Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

UK Health Body Approves Novartis's Tasigna For CML

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 01:16am CET

The U.K.'s health-cost regulator has decided to back an expensive cancer drug from Novartis AG (NVS) for treating chronic myeloid leukemia--but not one from U.S.-based Bristol-Myers Squibb Co. (BMY)--after the Swiss drug maker offered to cut the drug's price.

The independent National Institute for Clinical Excellence, known by its acronym NICE, said Wednesday it approved Novartis's Tasigna and the company's older drug, whose brand name is Glivec, for use in treating CML on the publicly funded National Health Service. The generic names for Tasigna and Glivec are nilotinib and imatinib, respectively.

However, NICE said it wasn't approving Bristol-Myers Squibb's Sprycel, also known as dasatinib.

CML is a cancer of blood-forming cells in the bone marrow that usually develops slowly, which is why it is described as a chronic form of the disease.

NICE director Carole Longson said: "The recommendations reaffirm the use of imatinib as an effective treatment for the majority of patients and a cost-effective use of NHS resources, and we are also very pleased to be able to add a further treatment option for these patients by recommending nilotinib.

"Although no trials directly comparing dasatinib and nilotinib were available, the committee concluded from indirect comparisons that dasatinib and nilotinib could be considered equally as effective in treating CML.

"However, the manufacturer of nilotinib has already agreed with the Department of Health to provide the drug to the NHS at a discounted price. This reduction in cost enabled the independent committee to approve nilotinib for use on the NHS."

Dasatinib and nilotinib both cost over GBP30,000 per patient a year and the standard dose of imatinib costs GBP20,000.

NICE didn't disclose the price discount offered by Novartis for nilotinib.

-By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY 0.53% 66.6 Delayed Quote.8.68%
NOVARTIS -1.05% 77.18 Delayed Quote.-5.34%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
03/16Ionis looks to Akcea for speedy launch of inotersen
03/15NOVARTIS : Researchers Submit Patent Application, "Chemical Process for Preparin..
03/15NOVARTIS : Patent Issued for Poly(Oxazoline-Co-Ethyleneimine)-Epichlorohydrin Co..
03/15NOVARTIS : Findings from Novartis in the Area of Guanylate Cyclase Reported [The..
03/15NOVARTIS : announces changes to the Executive Committee to support strategic pri..
03/14KNOW ABOUT PRIMARY CILIARY DYSKINESI : Key players profiled in this report Astra..
03/12NOVARTIS : Intent to Sole Source / ALCON Laboratories, Inc. Required Maintenance..
03/12NOVARTIS : J-- Intent to Sole Source / ALCON Laboratories, Inc. Required Mainten..
03/12NOVARTIS : expands alliance with Science 37 to advance virtual clinical trials p..
03/12GSK wins new reprieve as Hikma's generic Advair delayed again
More news
News from SeekingAlpha
03/18ETF MONTH #4 : Developed Markets (Ex-North America) With EFA. But Is There A Bet.. 
03/16RESTOR BIO : Stimulating Immune Responses In Elderly Populations 
03/14Updating Our Thoughts On Celgene 
03/13REGENXBIO : Substantial Unlocked Value In The MPS Franchises 
03/12GILEAD SCIENCES : The Future Is Complicated 
Financials ($)
Sales 2018 52 099 M
EBIT 2018 13 607 M
Net income 2018 8 905 M
Debt 2018 17 967 M
Yield 2018 3,69%
P/E ratio 2018 20,64
P/E ratio 2019 18,92
EV / Sales 2018 4,46x
EV / Sales 2019 4,26x
Capitalization 215 B
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 93,3 $
Spread / Average Target 14%
EPS Revisions
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Srikant Madhav Datar Independent Non-Executive Director
Pierre Landolt Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS-5.34%216 150
JOHNSON & JOHNSON-4.77%358 615
PFIZER0.99%218 946
ROCHE HOLDING LTD.-10.73%201 801
MERCK AND COMPANY-1.07%148 965
AMGEN8.25%136 727